2023
Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy
Khajir G, Press B, Lokeshwar S, Ghabili K, Rahman S, Gardezi M, Washington S, Cooperberg M, Sprenkle P, Leapman M. Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy. JNCI Cancer Spectrum 2023, 7: pkad099. PMID: 38085220, PMCID: PMC10733209, DOI: 10.1093/jncics/pkad099.Peer-Reviewed Original ResearchConceptsMagnetic resonance imaging-ultrasound fusionMRF-TBLow-risk diseaseSystematic biopsyLower riskRisk groupingProstate biopsyActive surveillanceHigh riskProstate cancer risk stratificationIntermediate-risk criteriaIntermediate-risk diseaseSystematic prostate biopsyCancer risk stratificationPrimary study objectiveNCCN guidelinesImage-guided approachLocalized cancerRisk stratificationBenign findingsProstate cancerClinical riskDiagnostic yieldRetrospective analysisBiopsyImpact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial
Bhatt A, Kosiborod M, Claggett B, Miao Z, Vaduganathan M, Lam C, Hernandez A, Martinez F, Inzucchi S, Shah S, de Boer R, Jhund P, Desai A, Fang J, Han Y, Comin‐Colet J, Drożdż J, Vardeny O, Merkely B, Lindholm D, Peterson M, Langkilde A, McMurray J, Solomon S. Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial. European Journal Of Heart Failure 2023, 25: 2177-2188. PMID: 37771274, DOI: 10.1002/ejhf.3043.Peer-Reviewed Original ResearchCOVID-19 diagnosisRisk of deathHeart failureEjection fractionPandemic onsetTrial participantsCOVID-19Death rateMajor hypoglycaemic eventsChronic heart failureTime of diagnosisCOVID-19 survivorsDiabetic ketoacidosisHypoglycaemic eventsClinical outcomesHF eventsCOVID-19 casesTreatment benefitClinical riskCardiovascular trialsDeath/DapagliflozinEvent ratesPatientsDiagnosisNeonatal Intensive Care Unit Latent Profiles of Maternal Distress: Associations With 5-Year Maternal and Child Mental Health Outcomes
Njoroge W, Gerstein E, Lean R, Paul R, Smyser C, Rogers C. Neonatal Intensive Care Unit Latent Profiles of Maternal Distress: Associations With 5-Year Maternal and Child Mental Health Outcomes. Journal Of The American Academy Of Child & Adolescent Psychiatry 2023, 62: 1123-1133. PMID: 37084882, PMCID: PMC10543383, DOI: 10.1016/j.jaac.2023.02.015.Peer-Reviewed Original ResearchConceptsNeonatal intensive care unitChild mental health outcomesPreterm infantsHealth outcomesMental health outcomesNICU stressReference listsHealth factorsSocial determinantsChildren age 5 yearsHigher depressionIntensive care unitLife stressDisparate health outcomesPoor health outcomesAge 5 yearsEthnic groupsNICU dischargeCare unitRisk dyadsChildren ages 5Clinical riskUniversal screeningMaternal symptomatologyAffective symptomsSelf‐report measure of parental reflective functioning: A study of reliability and validity across three samples of varying clinical risk
Carlone C, Milan S, Decoste C, Borelli J, McMahon T, Suchman N. Self‐report measure of parental reflective functioning: A study of reliability and validity across three samples of varying clinical risk. Infant Mental Health Journal Infancy And Early Childhood 2023, 44: 240-254. PMID: 36857469, DOI: 10.1002/imhj.22046.Peer-Reviewed Original ResearchConceptsClinical riskMajority of mothersSubstance use disordersParent Development InterviewParental reflective functioningParental Reflective Functioning QuestionnaireSample of mothersUse disordersFunctioning QuestionnaireInitial validation studyMental statesParent-report measuresMothersReflective functioningReflective Functioning QuestionnairePsychometric propertiesSelf-report measuresValidation studyParents' capacityRiskReliable measureAdditional supportParent-child relationshipUse of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation
Leapman M, Wang R, Loeb S, Seibert T, Gaylis F, Lowentritt B, Brown G, Chen R, Lin D, Witte J, Cooperberg M, Catalona W, Gross C, Ma X. Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. Journal Of Urology 2023, 209: 710-718. PMID: 36753746, DOI: 10.1097/ju.0000000000003159.Peer-Reviewed Original ResearchConceptsIntermediate-risk prostate cancerMixed-effects Poisson regressionPSA testingProstate biopsyProstate cancerEffects Poisson regressionMedicare beneficiariesPoisson regressionAdditional prostate biopsyRetrospective cohort studyProstate MRILocalized prostate cancerRepeat prostate biopsyRate of biopsyRace/ethnicityCensus tract povertyMedian followCohort studyMedian ageMonitoring testsProvider factorsPSA testClinical riskBiopsySociodemographic factors
2022
Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning.
Paulson N, Zeevi T, Papademetris M, Leapman MS, Onofrey JA, Sprenkle PC, Humphrey PA, Staib LH, Levi AW. Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning. JCO Clinical Cancer Informatics 2022, 6: e2200016. PMID: 36179281, DOI: 10.1200/cci.22.00016.Peer-Reviewed Original ResearchConceptsGrade group 2Prostate biopsyRadical prostatectomyAdverse outcomesGroup 2GG-2Core prostate biopsyProstate cancer outcomesPatient's clinical riskClinical risk assessmentCore needle biopsyOngoing clinical needAdverse outcome predictionRetrospective reviewAdverse pathologyCAPRA scoreEntire cohortCancer outcomesPathologic diagnosisNeedle biopsyClinical riskDisease outcomeProstate cancerBiopsyDisease one
2021
Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation
Thompson AD, Helms AS, Kannan A, Yob J, Lakdawala NK, Wittekind SG, Pereira AC, Jacoby DL, Colan SD, Ashley EA, Saberi S, Ware JS, Ingles J, Semsarian C, Michels M, Mazzarotto F, Olivotto I, Ho CY, Day SM. Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation. Genetics In Medicine 2021, 23: 1281-1287. PMID: 33782553, PMCID: PMC8257482, DOI: 10.1038/s41436-021-01134-9.Peer-Reviewed Original ResearchConceptsHypertrophic cardiomyopathyClinical riskMissense variantsSarcomeric Human Cardiomyopathy RegistryHigh clinical riskClinical risk stratificationAdverse eventsComposite endpointRisk stratificationHCM patientsCommon causePatientsLoss of functionUncertain significanceMYBPC3Missense VUSCardiomyopathyHigh rateSubstantial numberSupportive evidenceVUSRiskVariant interpretationEvent analysisMethodsAmongMental Health and Psychosocial Characteristics Associated With COVID-19 Among U.S. Adults
Tsai J, Huang M, Elbogen E. Mental Health and Psychosocial Characteristics Associated With COVID-19 Among U.S. Adults. Psychiatric Services 2021, 72: 444-447. PMID: 33530731, DOI: 10.1176/appi.ps.202000540.Peer-Reviewed Original ResearchConceptsCOVID-19 infectionMental healthCOVID-19Positive COVID-19 testCOVID-19 statusMental health characteristicsMiddle-income adultsCOVID-19 testSocial supportClinical riskHealth characteristicsPsychiatric historyNegative testHistory of homelessnessMedical needPsychosocial characteristicsU.S. adultsCurrent social supportInfectionHealthNational sampleAdultsVeterans
2020
Updates in periprocedural management of direct oral anticoagulants.
Tao J, Oprea AD. Updates in periprocedural management of direct oral anticoagulants. Current Opinion In Anaesthesiology 2020, 33: 423-431. PMID: 32371643, DOI: 10.1097/aco.0000000000000873.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsPeriprocedural managementOral anticoagulantsPrevalence of patientsDrug interruptionTrough levelsComplete clearanceProcedural riskPartial clearanceClinical riskAmerican CollegeElectrophysiology proceduresFavorable pharmacokineticsQuick onsetAnticoagulantsRiskClearanceDrugsReview detailsBleedingMedicationsManagementPatientsAntithromboticsAnesthesiologists
2019
Validation of a Machine Learning Model That Outperforms Clinical Risk Scoring Systems for Upper Gastrointestinal Bleeding
Shung DL, Au B, Taylor RA, Tay JK, Laursen SB, Stanley AJ, Dalton HR, Ngu J, Schultz M, Laine L. Validation of a Machine Learning Model That Outperforms Clinical Risk Scoring Systems for Upper Gastrointestinal Bleeding. Gastroenterology 2019, 158: 160-167. PMID: 31562847, PMCID: PMC7004228, DOI: 10.1053/j.gastro.2019.09.009.Peer-Reviewed Original ResearchConceptsUpper gastrointestinal bleedingHospital-based interventionsComposite endpointScoring systemRockall scoreGastrointestinal bleedingClinical riskConsecutive unselected patientsLow-risk patientsClinical scoring systemRisk-scoring systemExternal validation cohortCharacteristic curve analysisInternal validation setOutpatient managementUnselected patientsValidation cohortEmergency departmentMedical CenterGreater AUCPatientsAbstractTextCurve analysisEndpointAUCPD17-02 CLINICAL RISK BASED ASSOCIATIONS OF LYMPH NODE DISSECTION AND DETECTION YIELD AMONG MEN TREATED WITH RADICAL PROSTATECTOMY FOR PROSTATE CANCER
Abello* A, Sprenkle P, Kenney P, Leapman M. PD17-02 CLINICAL RISK BASED ASSOCIATIONS OF LYMPH NODE DISSECTION AND DETECTION YIELD AMONG MEN TREATED WITH RADICAL PROSTATECTOMY FOR PROSTATE CANCER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555562.32224.0f.Peer-Reviewed Original Research
2017
Safe Opioid Prescribing and Controlled Substance Policies
Tobin D, Barrette E. Safe Opioid Prescribing and Controlled Substance Policies. 2017, 157-180. DOI: 10.1007/978-3-319-68267-9_14.ChaptersUse of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
Krop I, Ismaila N, Andre F, Bast RC, Barlow W, Collyar DE, Hammond ME, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Wolff AC, Stearns V. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. Journal Of Clinical Oncology 2017, 35: jco.2017.74.047. PMID: 28692382, PMCID: PMC5846188, DOI: 10.1200/jco.2017.74.0472.Peer-Reviewed Original ResearchConceptsAdjuvant systemic therapyNode-positive breast cancerAdjuvant systemic chemotherapyHigh clinical riskBreast cancerSystemic therapyClinical riskSystemic chemotherapySuch patientsClinical utilityEarly-stage invasive breast cancerClinical Oncology Clinical Practice GuidelineNode-negative breast cancerOncology Clinical Practice GuidelineHuman epidermal growth factor receptor 2Early-stage breast cancerEpidermal growth factor receptor 2Triple-negative breast cancerGood-prognosis populationUse of MammaPrintInvolved lymph nodesGrowth factor receptor 2Invasive breast cancerClinical practice guidelinesClinical risk categories
2011
Ghrelin-induced hypothermia: A physiological basis but no clinical risk
Wiedmer P, Strasser F, Horvath TL, Blum D, DiMarchi R, Lutz T, Schürmann A, Joost HG, Tschöp MH, Tong J. Ghrelin-induced hypothermia: A physiological basis but no clinical risk. Physiology & Behavior 2011, 105: 43-51. PMID: 21513721, PMCID: PMC3146973, DOI: 10.1016/j.physbeh.2011.03.027.Peer-Reviewed Original ResearchConceptsGhrelin treatmentBody temperatureApplication of ghrelinMedial preoptic areaPotential anatomical basisCold-sensitive neuronsGhrelin infusionBody core temperatureChronic i.Positive energy balanceGhrelin receptorPreoptic areaAxon terminalsClinical riskFood intakeGhrelinHealthy humansSerious hypothermiaMale subjectsPhysiologic circumstancesAnatomical basisHypothermiaCold exposureRelevant decreaseEnergy expenditure
2010
When Is Door-to-Balloon Time Critical? Analysis From the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trials
Brodie BR, Gersh BJ, Stuckey T, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Grines CL, Cox D, Parise H, Prasad A, Lansky AJ, Mehran R, Stone GW. When Is Door-to-Balloon Time Critical? Analysis From the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trials. Journal Of The American College Of Cardiology 2010, 56: 407-413. PMID: 20650362, DOI: 10.1016/j.jacc.2010.04.020.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionLower mortality rateHigh-risk patientsPercutaneous coronary interventionMortality rateEarly presentationCoronary interventionClinical riskST-segment elevation myocardial infarctionSimilar relative risk reductionsHORIZONS-AMI trialElevation myocardial infarctionRelative risk reductionNon-percutaneous coronary intervention hospitalsMortality rate reductionImpact of doorCADILLAC trialHORIZONS-AMIAntithrombotic therapyReperfusion therapyBalloon timeIntervention hospitalsAbsolute benefitLate presentationMyocardial infarction
1994
Platelet-leukocyte activation and modulation of adhesion receptors in pediatric patients with congenital heart disease undergoing cardiopulmonary bypass
Rinder C, Gaal D, Student L, Smith B. Platelet-leukocyte activation and modulation of adhesion receptors in pediatric patients with congenital heart disease undergoing cardiopulmonary bypass. Journal Of Thoracic And Cardiovascular Surgery 1994, 107: 280-288. PMID: 8283897, DOI: 10.1016/s0022-5223(94)70482-1.Peer-Reviewed Original ResearchConceptsCongenital heart diseasePlatelet-leukocyte conjugatesNoncyanotic congenital heart diseaseCardiopulmonary bypassHeart diseasePediatric patientsNoncyanotic patientsLeukocyte activationPlatelet glycoprotein IbNeutrophil-platelet conjugatesPlatelet–leukocyte activationTermination of bypassCyanotic heart diseaseEnd of bypassMonocyte-platelet conjugatesGlycoprotein IbNoncyanotic heart diseaseActivation of plateletsInflammatory complicationsPulmonary dysfunctionCyanotic patientsPlatelet adhesion receptorsCD11b expressionClinical riskBaseline values
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply